EWTX

Edgewise Therapeutics($EWTX) Executives Sold Millions Before Clinical Failure Crash, While Institutions Bought $10M After Collapse

04/04/2025 23:45

Shares of Edgewise Therapeutics Inc ($EWTX) plummeted in early April following disappointing clinical trial results for its heart disease drug EDG-7500, but SEC filings reveal that company insiders had been conducting substantial stock sales for months prior. Even more intriguing is the $10 million purchase by major institutional investors immediately following the stock's collapse. On April 2, $EWTX shares dropped 39.4% in a single day after safety and efficacy concerns emerged regarding EDG-7500, with the decline continuing the following day to $13.58. This represents a more than 60% fall from its 52-week high of approximately $35 reached in mid-October last year. Notably, company executives had been consistently selling shares before this price collapse. According to SEC Form 4 filings, on September 20, 2024 alone, Officer Alan J Russell sold 75,000 shares ($2.17 million), CMO Joanne M Donovan sold 7,162 shares ($202,603), CBO Behrad Derakhshan sold 42,068 shares ($1.22 million), Officer John R Moore sold 50,000 shares ($1.42 million), and CFO R Michael Carruthers sold 125,092 shares ($3.57 million). This amounted to nearly 300,000 shares sold in a single day. The selling pattern continued with CDO Marc Semigran disposing of 29,709 shares ($887,423) on December 24, and Alan Russell selling an additional 100,000 shares ($2.74 million) on December 30. Into 2025, CMO Joanne Donovan sold 25,000 shares ($690,658) on January 28, with several more executives making additional sales in early February, and smaller dispositions continuing through March. In stark contrast, immediately following the share price collapse on April 3, OrbiMed Advisors LLC and Director Peter A Thompson each purchased 496,771 shares (approximately $10 million total) at $20.13 per share. These securities are held by OrbiMed Private Investments VI, LP, with the reporting persons disclaiming beneficial ownership except for their pecuniary interest. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for muscle disorders. Its key pipeline includes EDG-5506 for Duchenne and Becker muscular dystrophies (currently in Phase II trials) and EDG-7500 for hypertrophic cardiomyopathy (Phase I). As typical for clinical-stage biotech firms, $EWTX has no commercial revenue and reported net losses of approximately $134 million on a trailing twelve-month basis. Its most recent quarterly results (for the quarter ended September 30, 2024) showed a loss of $0.36 per share, slightly improved from the $0.41 loss in the same quarter of the previous year. $EWTX stock traded around $17-18 during the first half of 2024 before beginning an upward momentum in early July. On September 19, the stock surged from $19.07 to $29.50 in a single day (a 54.7% increase), ultimately reaching above $35 by mid-October. However, this upward trajectory was sharply reversed following the clinical results announcement in early April. According to news reports about the clinical failure, patients receiving EDG-7500 reported side effects including dizziness and respiratory infections, with one participant discontinuing the trial as a result. Analysts at RBC Capital Markets noted that Edgewise's drug showed modest efficacy markers compared to earlier studies, news that boosted competitor Cytokinetics' shares by 12%. Despite recent events, $EWTX still maintains a "Strong Buy" consensus among market experts, with an average price target of $41. However, the recent clinical setback and insider selling pattern raise questions about this optimistic outlook. In the biopharmaceutical industry, insider trading patterns are often interpreted as signals of internal confidence or concerns about major upcoming events such as clinical results or regulatory approvals. In $EWTX's case, executives consistently sold shares while the stock traded in the $20-30 range, followed by institutional buying after the price collapse. Considering $EWTX's current market position, investors should monitor the remaining pipeline, particularly EDG-5506 in Phase II trials, and the company's cash liquidity situation. Additionally, technical differentiation from competitors like Cytokinetics and market opportunities will be crucial factors in assessing long-term growth potential. Upcoming quarterly results and additional clinical data for EDG-5506 will likely serve as key catalysts determining $EWTX's next movements. Investors should carefully consider whether the institutional buying represents simply a bargain opportunity or reflects confidence in the company's long-term value proposition.

You can receive notifications when news is published.